Viral Vector Affinity Resin Market Report 2026

The viral vector affinity resin market size has grown rapidly in recent years. It will grow from $0.62 billion in 2025 to $0.72 billion in 2026 at a compound annual growth rate (CAGR) of 16.2%. The growth in the historic period can be attributed to expansion of viral vector research activities, increasing use of chromatography in bioprocessing, growth in gene therapy development programs, rising demand for scalable purification solutions, improvements in resin manufacturing technologies.

The viral vector affinity resin market size is expected to see rapid growth in the next few years. It will grow to $1.3 billion in 2030 at a compound annual growth rate (CAGR) of 15.9%. The growth in the forecast period can be attributed to increasing commercialization of gene therapies, rising demand for high-throughput purification platforms, expansion of vaccine development pipelines, growing focus on cost-efficient downstream processing, increasing adoption of customized affinity resins. Major trends in the forecast period include increasing adoption of high-capacity affinity resins, rising demand for aav and lentiviral purification solutions, growing use of single-use chromatography systems, expansion of ligand-specific resin development, enhanced focus on high-purity viral vector processing.

The increasing adoption of gene-based therapeutics is expected to drive growth in the viral vector affinity resin market. Gene-based therapeutics use DNA, RNA, or viral vectors to modify or regulate gene expression within patient cells. Adoption of these therapies is rising due to advances in delivery systems that enable safe, efficient, and targeted transport of genetic material into cells. Viral vector affinity resins support this growth by providing high-purity, scalable purification solutions, which are ideal for viral vector manufacturing. They help overcome downstream processing challenges by efficiently separating viral vectors from impurities, improving production efficiency, and supporting broader clinical and commercial applications. For instance, in December 2024, the American Society of Gene & Cell Therapy (ASGCT) reported that the U.S. FDA approved six gene therapy products in 2023, up from five in 2022. Therefore, the increasing adoption of gene-based therapeutics is driving the viral vector affinity resin market.

Rising healthcare expenditure is also expected to propel the viral vector affinity resin market. Healthcare expenditure includes spending on medical services, treatments, facilities, research, and public health initiatives to maintain or improve health outcomes. The increase is driven by the rising prevalence of chronic diseases, which require long-term and costly treatments. Higher healthcare expenditure boosts investments in advanced biomanufacturing and purification technologies, driving demand for high-quality viral vector production. Affinity resins ensure efficient purification, higher yields, and regulatory compliance, supporting these advanced therapies. For example, in May 2024, the UK Office for National Statistics reported a 5.6% increase in total healthcare expenditure in 2023, representing a 0.9% growth compared to 2022. Therefore, rising healthcare expenditure is fueling growth in the viral vector affinity resin market.

In terms of strategic expansion, Repligen Corporation, a U.S.-based biotechnology company, acquired Tantti Laboratory Inc. in July 2024 for an undisclosed amount. This acquisition aims to enhance viral vector affinity resin capabilities and strengthen high-throughput purification solutions for emerging modalities, such as viral vectors and nucleic acids, by integrating Tantti’s DuloCore bead technology with Avitide’s AVIPure affinity ligands. Tantti Laboratory Inc., based in Taiwan, develops chromatography resins for viral vector purification.

Major companies operating in the viral vector affinity resin market are Thermo Fisher Scientific, GE Healthcare Technologies Inc., Repligen Corporation, Creative Biolabs, JNC Corporation, Aptamer Group, ChromaGenix Inc., Cytiva (Danaher Corporation), Merck KGaA, Sartorius AG, Purolite Life Sciences, Tosoh Bioscience, Bio‑Rad Laboratories, Avantor Inc., Pall Corporation, Takara Bio Inc., Cube Biotech, Agilent Technologies, Promega Corporation, Kaneka Corporation.

North America was the largest region in the viral vector affinity resin market in 2025. The regions covered in the viral vector affinity resin market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the viral vector affinity resin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the viral vector affinity resin market by increasing costs of imported polymer matrices, recombinant ligands, chromatography hardware, and specialty chemicals required for resin production. Biopharmaceutical manufacturers in North America and Europe are most affected due to dependence on imported high-performance materials, while Asia-Pacific faces cost pressures on resin exports. These tariffs are increasing purification costs and affecting process economics. However, they are also driving domestic resin manufacturing, local ligand development, and regional supply chain strengthening for bioprocess materials.

The viral vector affinity resin market research report is one of a series of new reports that provides viral vector affinity resin market statistics, including viral vector affinity resin industry global market size, regional shares, competitors with a viral vector affinity resin market share, detailed viral vector affinity resin market segments, market trends and opportunities, and any further data you may need to thrive in the viral vector affinity resin industry. This viral vector affinity resin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Viral vector affinity resin is a specialized chromatography material engineered to selectively bind viral vectors based on their surface proteins or capsid structures. It enables efficient purification of viral vectors from complex mixtures, removing impurities such as host cell proteins, DNA, and empty capsids, to produce high-quality, high-titer viral preparations for research or therapeutic applications.

The main product types of viral vector affinity resin include adenoviral vector affinity resin, lentiviral vector affinity resin, adeno-associated viral (AAV) vector affinity resin, retroviral vector affinity resin, and others. Adenoviral vector affinity resin is a chromatography resin specifically designed to capture and purify adenovirus vectors based on their surface proteins or capsid structures. Applications include gene therapy, vaccine development, cell therapy, and more, serving end users such as pharmaceutical and biotechnology companies, academic and research institutes, and contract research organizations.

The viral vector affinity resin market consists of sales of viral vector purification resins, pre-packed chromatography columns, ancillary purification kits, and consumables. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.